Adial announces positive pre-clinical data for purnovate's pnv-5030 as a drug candidate for the treatment of pain

Results suggest potential of pnv-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction

ADIL Ratings Summary

ADIL Quant Ranking